Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan

Oku et al., Modern Rheumatology, doi:10.1093/mr/roac104

Oku et al., Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a.., Modern Rheumatology, doi:10.1093/mr/roac104

Sep 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 220 COVID-19 patients with rheumatic disease in Japan, showing no significant difference in mortality with remdesivir treatment.

[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

1. Gérard et al., Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145, Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database, https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2145.

2. Wu et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.692828, Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS, https://www.frontiersin.org/articles/10.3389/fphar.2022.692828/full.

3. Zhou et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.833679, Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis, https://www.frontiersin.org/articles/10.3389/fphar.2022.833679/full.

Important missing comments or errors? Let us know.

This study includes remdesivir and HCQ.

risk of death, 40.2% higher, RR 1.40, p = 0.59, treatment 3 of 46 (6.5%), control 8 of 172 (4.7%), unadjusted, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Oku et al., 6 Sep 2022, retrospective, Japan, peer-reviewed, 8 authors, study period 3 June, 2020 - 30 June, 2021.

Contact: horiuchi.takahiko.191@m.kyushu-u.ac.jp.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Remdesivir All

MORH-D-22-00049 Received: 20-Jan-2022; Accepted: 4-Aug-2022

Kenji Oku, Yasutaka Kimoto, Takahiko Horiuchi, Mari Yamamoto, Yasushi Kondo, Masashi Okamoto, Tatsuya Atsumi, Tsutomu Takeuchi, Y Makino, Matsubara Mayflower, Hospital Misaki

doi:10.1093/mr/roac104/6692611

Background: The incidence and prognosis of COVID-19 and rheumatic disease vary among ethnicities and regions. COVID-19 outcomes in rheumatic disease patients remain unclear, especially in the Asia-Pacific region. This study aimed to clarify the demographic and clinical factors that may influence COVID-19 prognosis in rheumatic disease patients.

Conflict of interest K. Oku, Y. Kimoto, T. Horiuchi, M. Yamamoto, Y. Kondo, M. Okamoto, and Tatsuya Atsumi have no conflicts of interest to declare. T.Takeuchi has received a speaking fee from Eli Lilly Japan K.K., and a research grant from Chugai Pharmaceutical Co.

References

Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218946

Bozzalla Cassione, Zanframundo, Biglia, Codullo, Montecucco et al., COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217717

Fernandez-Ruiz, Paredes, Niewold, COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease, Transl Res, doi:10.1016/j.trsl.2020.12.007

Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871

Hyrich, Machado, Rheumatic disease and COVID-19: epidemiology and outcomes, Nat Rev Rheumatol, doi:10.1038/s41584-020-00562-2

Kutsuna, Clinical Manifestations of Coronavirus Disease 2019, JMA J, doi:10.31662/jmaj.2021-0013

Listing, Gerhold, Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, doi:10.1093/rheumatology/kes305

Matsunaga, Hayakawa, Terada, Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN, Clin Infect Dis, doi:10.1093/cid/ciaa1470

Norena, Fernandez-Ruiz, Aguado, Viral infections in the biologic therapy era, Expert Rev Anti Infect Ther, doi:10.1080/14787210.2018.1521270

Raiker, Deyoung, Pakhchanian, Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States, Arthritis Rheum, doi:10.1016/j.semarthrit.2021.08.010

Raiker, Pakhchanian, Silva, Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network, J Autoimmun

Schioppo, Argolini, Sciascia, Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients, Rheumatology, doi:10.1093/rheumatology/keab611

Schmajuk, Montgomery, Leonard, Factors Associated With Hospitalization and Death After COVID-19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data, ACR Open Rheumatol, doi:10.1002/acr2.11328

Shin, Shin, Moon, Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(21)00151-X

Singh, Cameron, Noorbaloochi, Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis, Lancet, doi:10.1016/S0140-6736(14)61704-9

Sparks, Wallace, Seet, Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry, Ann Rheum Dis

Strangfeld, Schafer, Gianfrancesco, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219498

Thanou, Sawalha, SARS-CoV-2 and Systemic Lupus Erythematosus, Curr Rheumatol Rep, doi:10.1007/s11926-020-00973-w

Weckerle, Franek, Kelly, Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus, Arthritis Rheum, doi:10.1002/art.30187

Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit